Amlodipine vs Metoprolol

Both amlodipine and metoprolol effectively lower blood pressure, but through different mechanisms and with different response patterns across patient populations ^[1][2][3]. Amlodipine typically reduces systolic blood pressure by 10-15 mmHg and diastolic by 6-10 mmHg at standard doses (5-10 mg daily) ^[1]. Metoprolol (tartrate 50-200 mg twice daily or succinate 25-200 mg once daily) produces similar overall reductions, though blood pressure lowering may be less pronounced in certain populations ^[2][3].

The ALLHAT trial (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial), the largest antihypertensive trial ever conducted (33,357 patients), compared a CCB (amlodipine) to a diuretic (chlorthalidone) and an ACE inhibitor (lisinopril) ^[5]. Amlodipine was comparable to chlorthalidone for the primary endpoint (coronary heart disease events) and demonstrated excellent blood pressure control across all racial and age subgroups ^[5]. Notably, amlodipine showed particular efficacy in Black patients and elderly patients, populations where beta-blockers like metoprolol tend to be less effective as monotherapy ^[5][7].

Meta-analyses have questioned beta-blockers' position as first-line antihypertensive therapy. A 2006 Cochrane review by Wiysonge et al. found that atenolol-based regimens (and by extension, other beta-blockers) were inferior to other antihypertensive classes for preventing stroke and showed no superiority for preventing coronary heart disease or all-cause mortality ^[6]. While this evidence primarily involved atenolol rather than metoprolol specifically, it contributed to some guidelines downgrading beta-blockers from universal first-line status ^[6][7].

Metoprolol has strong evidence for specific cardiovascular indications beyond hypertension. It is a cornerstone of heart failure treatment (metoprolol succinate in the MERIT-HF trial reduced mortality by 34%), post-MI secondary prevention, and rate control in atrial fibrillation ^[2][4][8]. Amlodipine does not share these indications and is not used for heart failure (though it is safe to use in heart failure patients for blood pressure control, unlike some other CCBs) ^[1][3].

The side effect profiles of amlodipine and metoprolol reflect their different mechanisms and determine much of the clinical decision-making between them ^[1][2].

Amlodipine's most common side effect is peripheral edema (swelling of the ankles and feet), occurring in approximately 10-15% of patients at the 10 mg dose and 1-3% at 5 mg ^[1][3]. This dose-dependent edema results from precapillary arteriolar dilation without venous dilation, causing increased capillary hydrostatic pressure ^[1]. It is not responsive to diuretics but can be reduced by adding an ACE inhibitor or ARB (which dilate the venous side). Other common side effects include headache (7%), dizziness (3%), flushing (2-3%), and fatigue (4%) ^[1]. Amlodipine does not cause metabolic side effects — it does not affect glucose, lipids, or electrolytes ^[1][3].

Metoprolol commonly causes fatigue (10%), dizziness (10%), bradycardia (5-8%), cold extremities (1-3%), and sexual dysfunction (2-5%) ^[2][4]. Beta-blockers as a class can mask hypoglycemia symptoms in diabetic patients, worsen peripheral vascular disease symptoms, exacerbate bronchospasm in patients with reactive airway disease (though cardioselective agents like metoprolol are safer than non-selective beta-blockers), and cause weight gain (average 1-2 kg) ^[2][4][9]. Metoprolol can also cause depression, vivid dreams, and sleep disturbances in some patients ^[2][4].

Abrupt discontinuation of metoprolol can cause rebound tachycardia and hypertension due to upregulation of beta-receptors during chronic therapy, potentially triggering angina or MI in patients with coronary artery disease ^[2]. This necessitates gradual tapering over 1-2 weeks when discontinuing. Amlodipine can be stopped without a tapering requirement ^[1][3]. Both drugs have teratogenic potential and require careful consideration in pregnancy, though specific beta-blockers (labetalol) and CCBs (nifedipine) are commonly used for gestational hypertension ^[9].

Both medications are available as inexpensive generics. Generic amlodipine (5 mg or 10 mg tablets) typically costs $4-$10 per month and is included on most pharmacy $4 generic lists ^[10]. Generic metoprolol tartrate (25, 50, 100 mg tablets) costs $4-$10 per month for twice-daily dosing ^[10].

Metoprolol succinate extended-release (generic Toprol-XL) costs more at $10-$25 per month, though this once-daily formulation is preferred for its more consistent blood pressure and heart rate control ^[10]. Brand-name Norvasc and Toprol-XL cost $100-$200 per month but are rarely dispensed since generics are widely available.

Both are universally covered by insurance plans at preferred generic copay tiers. Neither requires additional monitoring costs (unlike some antihypertensives that require periodic electrolyte or renal function monitoring). The cost difference between these two drugs is not a significant factor in clinical decision-making for most patients.

Amlodipine has a notable convenience advantage in its pharmacokinetic profile. With a half-life of 30-50 hours — the longest of any commonly used antihypertensive — amlodipine is taken once daily and provides very consistent 24-hour blood pressure control ^[1][3]. This long half-life also makes it forgiving of missed doses; blood pressure remains controlled even if a dose is occasionally forgotten. It can be taken morning or evening, with or without food ^[1].

Metoprolol comes in two formulations with different dosing schedules. Metoprolol tartrate (immediate-release, generic Lopressor) has a 3-7 hour half-life and must be taken twice daily, which can reduce adherence ^[2]. Metoprolol succinate (extended-release, generic Toprol-XL) is taken once daily and provides more consistent 24-hour coverage, making it the preferred formulation for hypertension ^[2][4]. The succinate formulation should be swallowed whole (not crushed or split), though it can be taken with or without food ^[2].

Neither drug requires routine blood monitoring specifically for the medication, though periodic monitoring of blood pressure (and heart rate with metoprolol) is standard. Metoprolol requires a tapering schedule when discontinuing, adding a layer of complexity that amlodipine does not require ^[2]. Both are available in multiple tablet strengths for easy dose titration ^[1][2].

The choice between amlodipine and metoprolol should be guided by the patient's age, race, comorbidities, and specific treatment goals ^[5][7][9].

Amlodipine is generally preferred as first-line antihypertensive therapy for Black patients, elderly patients (over 65), and those with isolated systolic hypertension — populations where calcium channel blockers have shown superior efficacy and outcomes in large clinical trials ^[5][7]. It is also a strong choice for patients with Raynaud's phenomenon, stable angina (for its anti-anginal properties), or those who cannot tolerate beta-blocker side effects (fatigue, cold extremities, sexual dysfunction) ^[1][3]. Amlodipine is the better choice for patients with reactive airway disease (asthma or COPD) since it has no bronchoconstrictive effects ^[1].

Metoprolol is clearly preferred for patients with heart failure with reduced ejection fraction (one of only three beta-blockers with mortality reduction evidence: metoprolol succinate, carvedilol, bisoprolol), post-myocardial infarction secondary prevention, rate control in atrial fibrillation or atrial flutter, and migraine prevention ^[2][4][8]. For younger patients with hyperkinetic hypertension (elevated resting heart rate, palpitations, anxiety-related blood pressure surges), metoprolol addresses the underlying sympathetic overactivity more directly ^[4].

Many patients with difficult-to-control hypertension end up taking both medications together — the combination of a calcium channel blocker and a beta-blocker is safe and pharmacologically rational, as they lower blood pressure through complementary mechanisms ^[3][7]. However, patients should be monitored for excessive heart rate reduction when combining these classes.

Always work with your healthcare provider to choose the antihypertensive that best matches your individual cardiovascular risk profile, comorbidities, and tolerance for potential side effects.